BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/6/2023 8:08:49 AM | Browse: 147 | Download: 591
 |
Received |
|
2023-11-10 04:03 |
 |
Peer-Review Started |
|
2023-11-10 04:03 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2023-11-22 01:15 |
 |
Revised |
|
2023-11-23 02:07 |
 |
Second Decision |
|
2023-11-28 02:49 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2023-11-28 08:24 |
 |
Articles in Press |
|
2023-11-28 08:24 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2023-11-30 08:45 |
 |
Publish the Manuscript Online |
|
2023-12-06 08:08 |
ISSN |
2307-8960 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Medicine, General & Internal |
Manuscript Type |
Retrospective Study |
Article Title |
Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Gui-Cai Yuan, Ai-Zhen Chen, Wei-Xin Wang, Xu-Lan Yi, Long Tu, Fang Peng and Zhi-Hong Qiu |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Study on the efficacy and safety of tenofovir alafenamide in treating chronic hepatitis B patients with poor entecavir response |
SKJP22020201008. |
|
Corresponding Author |
Ai-Zhen Chen, N/A, Nurse, Department of Infectious Diseases, Yichun University Second Affiliated Hospital, No. 809 Yuanshan Middle Road, Yichun 336000, Jiangxi Province, China. caz996642292@163.com |
Key Words |
Entecavir; Tenofovir alafenamide; Chronic hepatitis B; Virologic response; Renal and bone toxicity; Suboptimal response |
Core Tip |
Switching from Entecavir (ETV) to Tenofovir alafenamide (TAF) is an effective and safe strategy for patients with chronic hepatitis B (CHB) who exhibit a suboptimal response to ETV. This switch improves virologic response rates and reduces the risk of viral resistance. TAF also demonstrates reduced renal and bone toxicity compared to Tenofovir disoproxil fumarate. This finding highlights the potential benefits of switching to TAF in managing CHB patients with suboptimal response to ETV, providing improved treatment outcomes and minimizing long-term safety concerns. |
Publish Date |
2023-12-06 08:08 |
Citation |
Yuan GC, Chen AZ, Wang WX, Yi XL, Tu L, Peng F, Qiu ZH. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir. World J Clin Cases 2023; 11(34): 8139-8146 |
URL |
https://www.wjgnet.com/2307-8960/full/v11/i34/8139.htm |
DOI |
https://dx.doi.org/10.12998/wjcc.v11.i34.8139 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345